Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.5365 EUR
−82.25 M EUR
35.10 M EUR
About scPharmaceuticals, Inc.
Sector
Industry
CEO
Michael E. Castagna
Website
Headquarters
Burlington
Founded
2013
ISIN
US8106481059
FIGI
BBG00KK7R6C1
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The firm's products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange scPharmaceuticals, Inc. stocks are traded under the ticker 2SX.
We've gathered analysts' opinions on scPharmaceuticals, Inc. future price: according to them, 2SX price has a max estimate of 10.25 EUR and a min estimate of 4.57 EUR. Watch 2SX chart and read a more detailed scPharmaceuticals, Inc. stock forecast: see what analysts think of scPharmaceuticals, Inc. and suggest that you do with its stocks.
Yes, you can track scPharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
scPharmaceuticals, Inc. is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
2SX earnings for the last quarter are −0.29 EUR per share, whereas the estimation was −0.25 EUR resulting in a −14.09% surprise. The estimated earnings for the next quarter are −0.21 EUR per share. See more details about scPharmaceuticals, Inc. earnings.
scPharmaceuticals, Inc. revenue for the last quarter amounts to 13.62 M EUR, despite the estimated figure of 13.08 M EUR. In the next quarter, revenue is expected to reach 16.37 M EUR.
2SX net income for the last quarter is −15.30 M EUR, while the quarter before that showed −18.25 M EUR of net income which accounts for 16.15% change. Track more scPharmaceuticals, Inc. financial stats to get the full picture.
No, 2SX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 14, 2025, the company has 164 employees. See our rating of the largest employees — is scPharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. scPharmaceuticals, Inc. EBITDA is −56.32 M EUR, and current EBITDA margin is −177.88%. See more stats in scPharmaceuticals, Inc. financial statements.
Like other stocks, 2SX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade scPharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.